Vis enkel innførsel

dc.contributor.authorSkarphedinsson, Gudmundur Águst
dc.contributor.authorWeidle, Bernhard
dc.contributor.authorIvarsson, Tord
dc.date.accessioned2017-12-18T12:45:29Z
dc.date.available2017-12-18T12:45:29Z
dc.date.created2015-10-08T09:26:46Z
dc.date.issued2015
dc.identifier.citationJournal of child and adolescent psychopharmacology. 2015, 25 (7), 574-579.nb_NO
dc.identifier.issn1044-5463
dc.identifier.urihttp://hdl.handle.net/11250/2472507
dc.description.abstractObjective: The purpose of this study was to investigate the effect of sertraline (SRT) in children and adolescents with obsessive-compulsive disorder (OCD) who did not respond to two consecutive courses of cognitive-behavior therapy (CBT). Methods: Observational study with 11 participants (males, n=6), 7–17 years of age with Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV) primary OCD. All had received 14 plus 10 sessions of CBT over the course of 218–532 days (mean=342.2, SD=85.5). Outcome measures were mean reduction of the Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS) total score and adequate clinical response (CY-BOCS<16). All participants received SRT (maximum dose 200 mg/day). The study was a part of the Nordic Long-Term OCD Treatment Study (NordLOTS). Results: Participants were treated with SRT over 72–300 days (mean=164.2, SD=68.3). The mean CY-BOCS score was reduced from 21.5 (SD=2.6) to 17.5 (SD=3.3). Only three participants obtained adequate clinical response (27.2%), and only two obtained >25% CY-BOCS total score reduction (close to 50%). Conclusions: A clinical response in approximately one third of the participants suggests that SRT treatment might be beneficial to a minority of patients who have consistently failed CBT.nb_NO
dc.language.isoengnb_NO
dc.publisherMary Ann Liebertnb_NO
dc.titleSertraline treatment of nonresponders to extended cognitive-behavior therapy in pediatric obsessive-compulsive disordernb_NO
dc.typeJournal articlenb_NO
dc.typePeer reviewednb_NO
dc.description.versionacceptedVersionnb_NO
dc.source.pagenumber574-579nb_NO
dc.source.volume25nb_NO
dc.source.journalJournal of child and adolescent psychopharmacologynb_NO
dc.source.issue7nb_NO
dc.identifier.doi10.1089/cap.2015.0041
dc.identifier.cristin1279150
dc.relation.projectNorges forskningsråd: 196291nb_NO
dc.description.localcodeThis is the authors' manuscript to the article (Preprint). Final publication is available from Mary Ann Liebert, Inc., publishers http://dx.doi.org/10.1089/cap.2015.0041nb_NO
cristin.unitcode194,65,35,5
cristin.unitnameRKBU Midt-Norge - Regionalt kunnskapssenter for barn og unge - psykisk helse og barnevern
cristin.ispublishedtrue
cristin.fulltextpreprint
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel